| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The Clayton Foundation Laboratories for Peptide Biology, The Salk Institute, La Jolla, California 92037; and Neurocrine Biosciences Inc., San Diego, California 92121
Address all correspondence and requests for reprints to: Catherine Rivier, Ph.D., The Salk Institute, 10010 North Torrey Pines Road, La Jolla, California 92037. E-mail: crivier{at}salk.edu.
We investigated the contribution of corticotropin-releasing factor (CRF) receptors types 1 and 2 (CRF1 and CRF2) in mediating the ACTH response to shock, alcohol injection, or endotoxemia in the rat. Peptidic (Astressin B and Astressin2-B) and nonpeptidic (NBI 30775) CRF antagonists were injected iv before the stressors at doses previously shown to be effective in blocking the corresponding receptors. Because NBI 30775, which specifically blocks CRF1, penetrates the brain following systemic injection, we also compared its effect with that of Astressin B, which primarily, though not exclusively, targets CRF1 but does not cross the blood-brain barrier. Shocks, alcohol (4.5 g/kg, intragastrically) or lipopolysaccharide (LPS, 1 µg/kg, iv) all significantly released ACTH. Astressin B or NBI 30775 markedly decreased the effect of shocks or alcohol and also interfered, though less significantly so, with the influence of LPS. In contrast, specific blockade of CRF2 with Astressin2-B, although not significantly altering the overall ACTH response to shocks, alcohol, or LPS, slightly enhanced ACTH levels during the early phase of some of these responses. Interestingly, combined administration of NBI 30775 and Astressin2-B decreased ACTH levels more than NBI 30775 alone, although this difference did not reach statistical significance. Finally, blockade of CRF1 and/or CRF2 augmented LPS- induced TNF-
and IL-6 release. Collectively, there results confirm the critical role played by CRF1 in mediating the ACTH response to shocks, alcohol and LPS, whereas the influence of CRF2 remains subtle. Finally, we showed that peripheral endogenous CRF restrains the ability of LPS to release cytokines.
This article has been cited by other articles:
![]() |
N. R Vulliemoz, E. Xiao, L. Xia-Zhang, J. Rivier, and M. Ferin Astressin B, a Nonselective Corticotropin-Releasing Hormone Receptor Antagonist, Prevents the Inhibitory Effect of Ghrelin on Luteinizing Hormone Pulse Frequency in the Ovariectomized Rhesus Monkey Endocrinology, March 1, 2008; 149(3): 869 - 874. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. C Moss, P. Anton, T. Savidge, P. Newman, A. S Cheifetz, J. Gay, S. Paraschos, M. W. Winter, M. P Moyer, K. Karalis, et al. Urocortin II mediates pro-inflammatory effects in human colonocytes via corticotropin-releasing hormone receptor 2{alpha} Gut, September 1, 2007; 56(9): 1210 - 1217. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Million, L. Wang, M. P. Stenzel-Poore, S. C. Coste, P. Q. Yuan, C. Lamy, J. Rivier, T. Buffington, and Y. Tache Enhanced pelvic responses to stressors in female CRF-overexpressing mice Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2007; 292(4): R1429 - R1438. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Li, P. Chen, J. Vaughan, K.-F. Lee, and W. Vale Urocortin 3 regulates glucose-stimulated insulin secretion and energy homeostasis PNAS, March 6, 2007; 104(10): 4206 - 4211. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Xiao, L. Xia-Zhang, N. Vulliemoz, J. Rivier, and M. Ferin Astressin B, a Corticotropin-Releasing Hormone Receptor Antagonist, Accelerates the Return to Normal Luteal Function after an Inflammatory-Like Stress Challenge in the Rhesus Monkey Endocrinology, February 1, 2007; 148(2): 841 - 848. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Wang, N. R. Basa, A. Shaikh, A. Luckey, D. Heber, D. H. St-Pierre, and Y. Tache LPS inhibits fasted plasma ghrelin levels in rats: role of IL-1 and PGs and functional implications. Am J Physiol Gastrointest Liver Physiol, October 1, 2006; 291(4): G611 - G620. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Kokkotou, D. Torres, A. C. Moss, M. O'Brien, D. E. Grigoriadis, K. Karalis, and C. Pothoulakis Corticotropin-releasing hormone receptor 2-deficient mice have reduced intestinal inflammatory responses. J. Immunol., September 1, 2006; 177(5): 3355 - 3361. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. N. Richardson, E. P. Zorrilla, C. D. Mandyam, and C. L. Rivier Exposure to Repetitive Versus Varied Stress during Prenatal Development Generates Two Distinct Anxiogenic and Neuroendocrine Profiles in Adulthood Endocrinology, May 1, 2006; 147(5): 2506 - 2517. [Abstract] [Full Text] [PDF] |
||||
![]() |
M Million, L Wang, Y Wang, D W Adelson, P-Q Yuan, C Maillot, S V Coutinho, J A Mcroberts, A Bayati, H Mattsson, et al. CRF2 receptor activation prevents colorectal distension induced visceral pain and spinal ERK1/2 phosphorylation in rats Gut, February 1, 2006; 55(2): 172 - 181. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Lodge and A. A. Grace Acute and Chronic Corticotropin-Releasing Factor 1 Receptor Blockade Inhibits Cocaine-Induced Dopamine Release: Correlation with Dopamine Neuron Activity J. Pharmacol. Exp. Ther., July 1, 2005; 314(1): 201 - 206. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Ma, M. J. Shipston, D. Morilak, and J. A. Russell Reduced Hypothalamic Vasopressin Secretion Underlies Attenuated Adrenocorticotropin Stress Responses in Pregnant Rats Endocrinology, March 1, 2005; 146(3): 1626 - 1637. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Gardiner, J. E. March, P. A. Kemp, A. P. Davenport, K. E. Wiley, and T. Bennett Regional Hemodynamic Actions of Selective Corticotropin-Releasing Factor Type 2 Receptor Ligands in Conscious Rats J. Pharmacol. Exp. Ther., January 1, 2005; 312(1): 53 - 60. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. F. Li, J. E. Bowe, S. L. Lightman, and K. T. O'Byrne Role of Corticotropin-Releasing Factor Receptor-2 in Stress-Induced Suppression of Pulsatile Luteinizing Hormone Secretion in the Rat Endocrinology, January 1, 2005; 146(1): 318 - 322. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Smith, J. M. Vaughan, C. J. Donaldson, J. Rivier, C. Li, A. Chen, and W. W. Vale Cocaine- and Amphetamine-Regulated Transcript Activates the Hypothalamic-Pituitary-Adrenal Axis through a Corticotropin-Releasing Factor Receptor-Dependent Mechanism Endocrinology, November 1, 2004; 145(11): 5202 - 5209. [Abstract] [Full Text] [PDF] |
||||
![]() |
A.-M. Samuelsson, I. Ohrn, J. Dahlgren, E. Eriksson, B. Angelin, B. Folkow, and A. Holmang Prenatal Exposure to Interleukin-6 Results in Hypertension and Increased Hypothalamic-Pituitary-Adrenal Axis Activity in Adult Rats Endocrinology, November 1, 2004; 145(11): 4897 - 4911. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. Walker, A. I. Su, D. W. Self, J. B. Hogenesch, H. Lapp, R. Maier, D. Hoyer, and G. Bilbe Applications of a Rat Multiple Tissue Gene Expression Data Set Genome Res., April 1, 2004; 14(4): 742 - 749. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Slominski, A. Pisarchik, D. J. Tobin, J. E. Mazurkiewicz, and J. Wortsman Differential Expression of a Cutaneous Corticotropin-Releasing Hormone System Endocrinology, February 1, 2004; 145(2): 941 - 950. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Kariagina, D. Romanenko, S.-G. Ren, and V. Chesnokova Hypothalamic-Pituitary Cytokine Network Endocrinology, January 1, 2004; 145(1): 104 - 112. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |